The therapeutic nuclear medicine market is foreseen to register a CAGR of 4.10% from 2024 to 2034, with a market valuation of USD 1.32 billion in 2024. Developing demand is invoked to set a valuation of USD 1.97 billion in 2034 for the market.
| Attributes | Details |
|---|---|
| Market Value for 2024 | USD 1.32 billion |
| Market Value for 2034 | USD 1.97 billion |
| Market Forecast CAGR for 2024 to 2034 | 4.10% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The historical CAGR of 11.70% was recorded for the market and a 4.10% CAGR is calculated through 2034. The market is evolving with the introduction of the product in palliative therapy, taking advantage of the lack of response to different treatments for distressing bone metastasis.
| Attributes | Details |
|---|---|
| Historical CAGR for 2019 to 2023 | 11.70% |
Acute aspects that are anticipated to influence the demand for the product through 2034 include:
Principal Consultant
Cancer and Cardiovascular Diseases See Stakes Rise in the Demand for the Market
The Geriatric Population Demands Innovation in the Industry
Establishments Perform Novel Research and Development in Therapeutic Nuclear Medicine
The following part offers an in-depth segmental analysis of the therapeutic nuclear medicine market. The demand for Radium-223 is significant, whereas the demand for prostate cancer treatment is anticipated to be augmented in 2024.
| Attributes | Details |
|---|---|
| Top Radionuclide Type | Radium-223 |
| Market share in 2024 | 77.50% |
The demand for Radium-223 is significant, slotted in to acquire a market share of 77.5% in 2024. The following aspects aid the development of demand for Radium-223:
| Attributes | Details |
|---|---|
| Top Indication | Prostate Cancer |
| Market share in 2024 | 55.60% |
Prostate cancer is penned in to acquire a market share by indication of 55.6% in 2024. The following aspects aid the development of the medicines in prostate cancer treatment:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
According to derived data, the demand from European countries is supposed to augment the sales growth of the medicines in the forthcoming decade. The industry in France and Germany is developing steeply. The therapeutic nuclear medication industry in the United Kingdom is anticipated to register a subordinate CAGR compared to other European nations. The demand for treatment is developing rapidly in Italy and Russia.
| Countries | CAGR from 2024 to 2034 |
|---|---|
| Russia | 6.4% |
| Germany | 4.4% |
| Italy | 5.4% |
| United Kingdom | 3.5% |
| France | 5.0% |
Through 2034, the therapeutic nuclear medicine industry in Russia is anticipated to register a 6.4% CAGR, owing to the development of prominent and emerging pharmaceutical and neurological research organizations.
In Russia, nuclear medicine is used to diagnose and treat various diseases, particularly cardiovascular and neurological conditions, but the key focus has always been placed on oncology.
The demand for these medicines is projected to report a CAGR of 4.4% in Germany by 2034 due to the prevalence of chronic diseases such as neuroendocrine tumors, prostate cancer, meningiomas, thyroid cancer, and lymphoma.
As therapeutic nuclear drugs are considered effective drugs for the treatment of cancer in the initial stages, thus German research and development organizations are developing novel radiopharmaceutical therapies.
Although therapeutic nuclear treatments’ future seems promising in the country, the German health regulatory bodies plummet the growth rate of radiopharmaceutical therapies.
The demand for these medicines in Italy is anticipated to showcase a CAGR of 5.4% between 2024 and 2034 as geriatric patients grow nationwide. The Italian medical environment targets the research and development of effective nuclear treatments that can aid in senior health.
The demand for these medicines in France is projected to report a CAGR of 5.0% from 2024 to 2034, as the French field of nuclear medicine and theranostics is developing rapidly. France has over two hundred nuclear medicine departments that use radionuclides for diagnostic or therapeutic objectives in various domains such as oncology, cardiology, neurology, or endocrinology. The medical community is promoting therapeutic nuclear treatment in healthcare environments.
Sales of therapeutic nuclear medicines in the United Kingdom are set to witness a CAGR of 3.5% through 2034. Therapeutic nuclear medicine in the United Kingdom has developed fairly inconsistently over the last half-century.
Nonetheless, the regular climate shifts in the United Kingdom have created a prevalence of cardiovascular illnesses, necessitating the use of therapeutic nuclear medication. The rising geriatric population in the United Kingdom demands innovation in radioisotope therapies aiding in the treatment of prostate cancer.
The therapeutic nuclear medicine industry’s dynamics are changing, and the key market players are vying for the majority stake in the competitive environment. Market players are implementing organic marketing techniques such as mergers and acquisitions, collaborations, and product launches to acquire a competitive advantage.
Top players produce the majority of nuclear medicine treatment products. Industry leaders have built their position in the market by investing more in research and having a better distribution system.
Recent technological developments in nuclear imaging modalities and the introduction of innovative pharmaceuticals into the global market have given the industry a huge boost. Continued and persistent research and development activities that result in betterment in new application areas are pushing market expansion.
Recent Developments in the Therapeutic Nuclear Medicine Market
The market is set to be valued at USD 1.32 billion in 2024.
The therapeutic nuclear medicine industry is anticipated to be valued at USD 1.97 billion by 2034.
In the United Kingdom, demand is anticipated to develop at a CAGR of 3.5% by 2034.
The therapeutic nuclear medicine industry is projected to register a CAGR of 4.10% from 2024 to 2034.
Therapeutic nuclear medicine industry has the following segments: treatment, indication, and distribution channel.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment 5.1. Radium-223 5.2. Iodine-131 5.3. Leutitium-177 5.4. Yttrium-90 5.5. Samarium-153 5.6. Strontium-89 5.7. Rhenium-188+Rhenium-186 5.8. Erbium-169 5.9. Phosphorous-32 5.10. Others 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication 6.1. Prostate Cancer 6.2. Painful Bone Metastases 6.3. Thyroid Cancer 6.4. Neuroblastoma 6.5. Synovitis 6.6. Non-Hodgkin’s Lymphoma 6.7. Hepatic Metastases 6.8. Brain Tumour 6.9. Others 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 7.1. Hospitals 7.2. Ambulatory Surgical Centres 7.3. Cancer Research Institutes 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Bayer AG 18.2. GE Healthcare 18.3. Novartis AG 18.4. Cardinal Health Inc. 18.5. Mallinckrodt plc. 18.6. Lantheus Medical Imaging Inc. 18.7. Bracco Imaging S.p.A 18.8. Eckert & Ziegler 18.9. Curium Pharma 18.10. International Isotopes Idaho, Inc. 18.11. Medi-Radiopharma Co., Ltd. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Therapeutic Nuclear Medicine Market
